What is Claimed:

1. A tablet for oral administration which contains deferasirox or a pharmaceutically acceptable salt thereof present in an amount of from 45% to 60% by weight based on the total weight of the tablet, and wherein the tablet contains 90 mg, 180 mg or 360 mg of deferasirox or a pharmaceutically acceptable salt thereof, wherein the tablet further comprises,

   (i) at least one filler in a total amount of 10% to 40 % by weight based on total weight of the tablet, wherein the filler is microcrystalline cellulose;

   (ii) at least one disintegrant in a total amount of 1% to 10% by weight based on the total weight of the tablet, wherein the disintegrant is cross-linked polyvinylpyrrolidone (crospovidone);

   (iii) at least one binder in a total amount of 1% to 5% by weight based on the total weight of the tablet, wherein the binder is polyvinylpyrrolidone (PVP);

   (iv) at least one surfactant in a total amount of 0.0% to 2% by weight based on the total weight of the tablet, wherein the surfactant is poloxamer;

   (v) at least one glidant in a total amount of 0.1% to 1% by weight based on the total weight of the tablet, wherein the glidant is colloidal silicon dioxide;

   (vi) at least one lubricant in a total amount of less than 0.1% to 2% by weight based on the total weight of the tablet, wherein the lubricant is magnesium stearate; and

   (vii) optionally, a coating.

2. The tablet for oral administration according to claim 1, wherein the tablet contains 90 mg of deferasirox or a pharmaceutically acceptable salt thereof.

3. The tablet for oral administration according to claim 1, wherein the tablet contains 180 mg of deferasirox or a pharmaceutically acceptable salt thereof.

4. The tablet for oral administration according to claim 1, wherein the tablet contains 360 mg of deferasirox or a pharmaceutically acceptable salt thereof.

5. The tablet for oral administration according to any one of the preceding claims, wherein the tablet exhibits a disintegration time of 5-10 minutes.

6. A tablet for oral administration consisting of 90 mg deferasirox;
   53.61 mg microcrystalline cellulose;
   3.65 mg polyvinylpyrrolidone;
   11.34 mg crospovidone;
   0.16 mg poloxamer;

0.81 mg colloidal silica;
2.43 mg magnesium stearate; and
optionally, 4.86 mg coating.

7. A tablet for oral administration consisting of 180 mg deferasirox;
107.23 mg microcrystalline cellulose;
7.29 mg polyvinylpyrrolidone;
22.68 mg crospovidone;
0.32 mg poloxamer;
1.62 mg colloidal silica;
4.86 mg magnesium stearate; and
optionally, 9.72 mg coating.

8. A tablet for oral administration consisting of 360 mg deferasirox;
215.45 mg microcrystalline cellulose;
14.58 mg polyvinylpyrrolidone;
45.36 mg crospovidone;
0.65 mg poloxamer;
3.24 mg colloidal silica;
9.72 mg magnesium stearate; and
optionally, 19.44 mg coating.